IVF pregnancy?
Yes 9 (11%)
No 75 (89%)
Known to have BRCA mutation?
Yes 3 (4%)
No 69 (82%)
Missing 12 (14%)
__________________________________________________________________________
*IQR = interquartile range
Table 2. Presentation at diagnosis
Characteristic Median (IQR*, range) or No of patients (%)
Gestational age at diagnosis (weeks) 25 (16-33, 2 to 40) N= 84 (100%)
<14 18 (21%)
14 - 6 23 (28%)
27 - 36 32 (38%)
37 - 40 5 (6%)
Missing 6 (7%)
Symptoms
Asymptomatic 2 (2%)
Symptomatic 76 (91%)
Missing 6 (7%)
Lump only 50 (60%)
Lump with or without other symptoms 70 (83%)
Pain / tenderness with or without other symptoms 13 (16%)
Skin changes / nipple inversion with or without other symptoms 10 (12%)
Other symptoms 2 (2%)
Clinical size of tumour at diagnosis (mm) 26 (20-40, 7 to 120) N= 84
(100%)
≤ 20 14 (17%)
30 – 50 37 (44%)
> 50 6 (7%)
Missing 27 (32%)
Interval from symptoms to diagnosis (weeks) 3 (2-9, 0 to 56) N= 84
(100%)
0 - 4 45 (53%)
5 - 9 10 (12%)
10 – 14 8 (9%)
15 – 19 1 (1%)
20 – 24 1 (1%)
>24 5 (6%)
Missing 10 (18%)
__________________________________________________________________________
*IQR = interquartile range
Table 3. Tumour characteristics and staging
Characteristic ER (+) ER (-) Total*
41(49%) 29 (35%) 84 (100%)
Histological grade
1 0 (0%) 0 (0%) 1 (1%)
2 12 (29%) 3 (10%) 15 (18%)
3 25 (60%) 19 (66%) 45 (53%)
N/A 1 (2%) 2 (7%) 4 (5%)
Missing 4 (9%) 5(17%) 19 (23%)
Histological type
Ductal 37 (90%) 23 (79%) 62 (74%)
Lobular 1 (2%) 1 (3%) 3 (4%)
Ductal and lobular 1 (2%) 0 (0%) 1 (1%)
Metaplastic 0 (0%) 1 (3%) 1 (1%)
Poorly differentiated 0 (0%) 2 (7%) 2 (2%)
DCIS 2 (5%) 0 (0%) 2 (2%)
Missing 0 (0%) 2 (7%) 13 (16%)
Distribution of cancer
Localised 26 (63%) 22 (76%) 51 (61%)
Multifocal 11 (27%) 4 (14%) 15 18%)
Missing 4 (10%) 3 (10%) 18 (62%)
PR Status
Positive 23 (56%) 1 (3%) 25 (30%)
Negative 5 (12%) 26 (90%) 31 (37%)
Missing 13 (32%) 2 (7%) 28 (33%)
HER2 Status
Positive 15 (37%) 8 (28%) 24 (28%)
Negative 25 (61%) 20 (69%) 45 (54%)
Missing 1 (2%) 1 (3%) 15 (18%)
Pathological T stage
T1 14 (34%) 6 (21%) 20 (24%)
T2 17 (42%) 11 (38%) 30 (36%)
T3 5 (12%) 6 (21%) 12 (14%)
T4 1 (2%) 2 (7%) 4 (5%)
Missing 4 (10%) 4 (13%) 18 (21%)
N Stage
N0 14 (34%) 10 (35%) 25 (30%)
N1 10 (25%) 5 (17%) 17 (21%)
N2 3 (7%) 4 (14%) 7 (8%)
N3 3 (7%) 4 (14%) 7 (8%)
Missing 11 (27%) 6 (20%) 28 (33%)
M Stage
M0 39 (95%) 26 (90%) 68 (81%)
M1 1 (2%) 2 (7%) 4 (5%)
Missing 1 (2%) 1 (3%) 12 (14%)
__________________________________________________________________________
ER: estrogen receptor; HER2: human epidermal growth factor receptor 2;
PR: progesterone receptor.
DCIS: Ductal carcinoma in situ
*ER status unknown for 14 women